LBPS / 4D pharma sees early success as phase I/II cancer trial hits its efficacy target early

4D pharma PLC said results from a phase II evaluation of its key irritable bowel treatment LBP Blautix have appeared in a peer-reviewed scientific pub more_horizontal

4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) will deliver what's called a ‘trial in progress' poster at a world-leading cancer conference outlining the pla more_horizontal

4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) said it will present an update from the phase I/II trial of its putative asthma treatment at an industry confere more_horizontal

4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) has some significant milestones upcoming this year after a successful 12 months of developing assets that target more_horizontal

4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) jumped 27% in London trading after the company hit its primary efficacy target in a phase I/II trail of one of i more_horizontal

4D pharma plc (NASDAQ: LBPS) has announced interim results from Phase 1/2 study evaluating the combination of MRx0518 and Merck & Co Inc's (NYSE: more_horizontal

4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) said it had hit its primary efficacy target in a phase I/II trial of one of its lead assets in kidney cancer. MR more_horizontal

4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) has received the green light for a first-in-human trial of its Parkinson's disease candidates in the US. This is more_horizontal